Proteomic Profiles in Acute Respiratory Distress Syndrome Differentiates Survivors from Non-Survivors

Maneesh Bhargava1*, Trisha L. Becker1, Kevin J. Viken1, Pratik D. Jagtap2, Sanjoy Dey3, Michael S. Steinbach3, Baolin Wu4, Vipin Kumar3, Peter B. Bitterman1, David H. Ingbar1, Christine H. Wendt1,5

1 Department of Medicine, University of Minnesota, Minneapolis, Minnesota, United States of America, 2 Minnesota Supercomputer Institute, University of Minnesota, Minneapolis, Minnesota, United States of America, 3 Department of Computer Science and Engineering, University of Minnesota, Minneapolis, Minnesota, United States of America, 4 School of Public Health, University of Minnesota, Minneapolis, Minnesota, United States of America, 5 Minneapolis VA Medical Center, University of Minnesota, Minneapolis, Minnesota, United States of America

Abstract

Acute Respiratory Distress Syndrome (ARDS) continues to have a high mortality. Currently, there are no biomarkers that provide reliable prognostic information to guide clinical management or stratify risk among clinical trial participants. The objective of this study was to probe the bronchoalveolar lavage fluid (BALF) proteome to identify proteins that differentiate survivors from non-survivors of ARDS. Patients were divided into early-phase (1 to 7 days) and late-phase (8 to 35 days) groups based on time after initiation of mechanical ventilation for ARDS (Day 1). Isobaric tags for absolute and relative quantitation (iTRAQ) with LC MS/MS was performed on pooled BALF enriched for medium and low abundance proteins from early-phase survivors (n = 7), early-phase non-survivors (n = 8), and late-phase survivors (n = 7). Of the 724 proteins identified at a global false discovery rate of 1%, quantitative information was available for 499. In early-phase ARDS, proteins more abundant in survivors mapped to ontologies indicating a coordinated compensatory response to injury and stress. These included coagulation and fibrinolysis; immune system activation; and cation and ion homeostasis. Proteins more abundant in early-phase non-survivors participate in carbohydrate catabolism and collagen synthesis, with no activation of compensatory responses. The compensatory immune activation and ion homeostatic response seen in early-phase survivors transitioned to cell migration and actin filament based processes in late-phase survivors, revealing dynamic changes in the BALF proteome as the lung heals. Early phase proteins differentiating survivors from non-survivors are candidate biomarkers for predicting survival in ARDS.

Introduction

Acute Respiratory Distress Syndrome (ARDS) is characterized by the abrupt onset of tachypnea, hypoxia, and loss of lung compliance in response to infectious or inflammatory triggers [1]. Extensive research has improved our understanding of ARDS pathophysiology [2], epidemiology [3,4], treatment options [5–7], and outcomes [3,8], yet ARDS patients continue to have a high mortality rate. There is strong interest in identifying biomarkers to predict the development of ARDS in at-risk subjects [9–11], assist in diagnosis [12–15], and inform prognosis [13,16–20]. Biomarkers enabling risk stratification would not only be useful in the clinical care setting, but also in clinical trials of new therapeutic interventions to phenotype clinical trial subjects and serve as surrogate endpoints.

Development of ARDS is associated with the activation of a large number of inflammatory mediators that damage the alveolar epithelium, endothelium, and basement membrane. Biomarkers based on the tissue of origin have been studied in both single center studies [11,21,22] and in NHLBI ARDS network cohorts [13,16,21]. Most studies have focused on investigating an individual biomarker in blood, bronchoalveolar lavage fluid (BALF), or urine. Markers of inflammation such as interleukin-1β [23], interleukin 6 [7], and soluble TNF receptor I and II [24] are associated with poor prognosis in ARDS. Markers of endothelial damage including ICAM-1 [7,21], Angiopoietin (Ang) [13], and Von Willebrand Factor (vWF) [25] correlate with higher mortality from ARDS. Poorer outcomes are also associated with higher plasma levels of SP-D (but not SP-A), a marker of type 2 alveolar epithelial cell damage [19], and receptor of advance glycation end products (RAGE), a marker of type 1 alveolar epithelial cell damage. Several other molecules, such as those involved in coagulation [26], damage to extracellular matrix [20], and oxidative stress (urine NO) [20], correlate with ARDS outcomes. A combination of biomarkers and clinical predictors...
was found to be superior to clinical predictors or biomarkers alone for predicting mortality in ARDS [27]. However, the identification of a single biomarker or a combination of biomarkers that could be widely used has remained elusive [28] due to lack of correlation between the biochemical marker, pathophysiological variables and clinical outcomes.

The primary aim of this study was to identify pathways of survival and stimulate new biomarker discovery by characterizing the BALF protein expression profile of ARDS survivors and non-survivors at different stages (early versus late) of disease progression. We analyzed medium and low abundant protein fractions in BALF samples by using contemporary high-resolution mass spectrometry (MS)-based proteomics techniques, along with quantitative labeling methodology. Our hypothesis was that patients who are able to survive ARDS would exhibit a distinct BALF protein profile during the early phase of mechanical ventilator support. Here, we show distinct differences in the BALF proteome between patients who survive ARDS from those who die. Moreover, the ontologies of differentially expressed proteins in late-phase survivors (cell migration and actin cytoskeleton organization) differ markedly from those in early-phase survivors, suggesting a critical role for these processes during lung repair. Enhancing these processes may provide new directions for therapy in ARDS.

Methods

Study population

The University of Minnesota Institutional Review Board Human Subjects Committee approved this study. Patients were recruited at the University of Minnesota Medical Center. Informed consent for study participation was obtained from either the patient or the patient’s legal representative. The early-phase ARDS BALF samples were available from clinically indicated bronchoscopies with excess supernatant made available for these studies. The late-phase ARDS samples were excess supernatant BALF obtained from research bronchoscopies with consent from the patient or the surrogate. BAL (100 mls normal saline) was performed using standard protocol in either the right middle lobe or left upper lobe (lingual).

For this study, patients were grouped based on the timing of the bronchoscopy – conducted in either the early phase of ARDS (Day 1–7) or the late phase (Day 8–35), referenced to the initiation of mechanical ventilation (designated Day 1) – and the outcome at the time of discharge (non-survivor or survivor). We thus studied patients in the early phase who were grouped into survivors or non-survivors and late-phase survivors. Late phase non-survivors were not included in this study as not enough BALF was available to perform the protein expression profile. The APACHE-II score was calculated to assess the severity of illness on the day of bronchoscopy for patients in early phase of ARDS as previously described [29].

Sample preparation

BALF samples were processed as previously described [30] with some modifications. BALF containing equal amounts of protein from individual patients were pooled to collect a total of 4 mg protein for each group (early-phase survivors, early-phase non-survivors, and late-phase survivors). Pooled BALF was concentrated and desalted by centrifugation with an Amicon 3-MWCO spin filter (Millipore, catalog number UFC800396). To decrease the dynamic range, we enriched the medium and low abundance proteins by selectively immunodepleting the fourteen most abundant proteins in the concentrated samples on Seppro IgY 14 spin columns (Sigma-Aldrich, cat # SEP010). The Seppro IgY 14 spin columns deplete albumin, IgG, α1-antitrypsin, IgA, IgM, transferrin, haptoglobin, α2-macroglobulin, fibrinogen, complement C3, α2-acute glycoprotein, apolipoproteins A-I, A-II and B. Per the manufacturer’s instructions, each sample was mixed in the dilution buffer to a final volume of 300 μl, loaded onto the immunodepletion column, and incubated for 15 minutes at room temperature. To prevent saturation of the column, 250 μg of protein was depleted at a time. The unbound medium and low abundance proteins were collected in the flow through. Pooled samples from each representative group was required to have adequate protein concentrations since immunodepletion results in >90% of the proteins being removed. An additional wash was performed with 0.5 ml of the dilution buffer. The depleted samples were then concentrated with an Amicon filter. A buffer exchange with 0.5 M triethylammonium bicarbonate (TEAB) was performed to remove TRIS, and the sample was concentrated with an Amicon filter. A Bradford protein assay was performed to quantify the enriched low abundant proteins.

iTRAQ labeling and 2D LC-Orbitrap MS

Enriched medium and low abundance proteins (50 μg from early-phase survivors and non-survivors, 25 μg from late phase survivors) were digested by trypsin and labeled with iTRAQ reagent (AB Scies, Foster City, CA) [30] for mass spectrometric analysis. The total peptide mixture was purified with an MCX Oasis cartridge (Waters, Milford, MA) before separation via two-dimensional liquid chromatography-mass spectrometry (2D LC-MS). LC and MS experimental details were previously reported [30]. Proteins were separated and concentrated offline in the 1st dimension into 15 peptide-containing fractions, collected in 2-minute intervals on a C18 Gemini column (Phenomenex, Torrance, CA) at pH 10, and in the 2nd dimension by a C18 reversed phase capillary LC with a nano LC system (Eksigent, Dublin, CA). Data-dependent acquisition of the 6 most intense peaks per LC fraction was performed on an Orbitrap Velos system, with HCD (higher energy collision induced dissociation) as the activation type for peptide tandem MS.

Database search for protein identification and quantification

Each of the 15 RAW files generated from the Orbitrap Velos MS system were converted to mzML files by using msconvert, then converted to a ProteinPilot compatible Mascot Generic Format (MGF) with preselected iTRAQ reporter ions. The MGF files were searched against the Human UniProt database along with contaminant protein sequences (84,838 sequences in total; December 2012) using ProteinPilot version 4.5 and the following search parameters: Sample Type: iTRAQ 4-plex (peptide labeled); Cys-alkylation: MMTS; Instrument: Orbitrap Velos; enzyme(s): Trypsin; mass tolerance: 10 ppm (10.000000); fragment mass differences for iTRAQ ratios (290.0891 and 290.1484 Da) were included. The ProteinPilot searches and subsequent generation of PSPEP (FDR) reports and protein and peptide-level summaries were generated within Galaxy-P [31]. Because MS data acquisition was performed on BALF samples after depletion of 14 high abundance plasma proteins, the high abundance proteins (or their fragment) were manually removed if they were present in the list of inferred proteins generated by ProteinPilot. Protein Summary with iTRAQ ratios (with early-phase survivors as the denominator for determining fold change) was processed through a workflow built within Galaxy-P so that it yielded UniProt accession numbers and gene names of differentially expressed proteins. The mass
spectrometry proteomics data have been deposited to the ProteomeXchange Consortium [32] via the PRIDE partner repository with the dataset identifier PXD001095.

Statistical analysis
Differences in the clinical characteristics of the three participant groups were calculated by using ANOVA and, when appropriate, a post hoc Tukey test. For protein identification and quantification, multiple hypothesis correction was performed by controlling for false discovery rate (FDR), which measures the expected proportion of false positives among the statistically significant findings. The FDR cutoff was set at 1% (global) for protein identification in ProteinPilot. For quantification of protein abundance, each ratio (obtained by comparison of early-phase non-survivors to survivors or late-phase survivors to early-phase survivors) was compared to one; multiple hypothesis correction was performed by controlling the FDR set at 5% [33] and computing q-values with the mafdr routine in Matlab. Proteins with q-values less than 0.05 were retained for further analysis.

Gene Ontology (GO) Enrichment Analysis
To gain insight into the biological significance of differentially expressed proteins, we used the Database for Annotation, Visualization, and Integrated Discovery (DAVID, http://david.abcc.ncifcrf.gov, search date 7/11/13) [34]. DAVID provides batch annotations to highlight the most relevant GO term associated with a gene (or protein) list. Of the three GO terms annotated to a gene (molecular function, biological process, and

### Table 1. Demographic and Clinical Characteristics of Subjects by Study Group.

| Variable                          | Early-phase ARDS survivors (N = 7) | Early-phase ARDS non-survivors (N = 8) | Late phase ARDS survivors (N = 7) | p-value * |
|-----------------------------------|------------------------------------|----------------------------------------|-----------------------------------|-----------|
| Age                               | 42.29 ± 11.43                      | 58.13 ± 20.49                         | 47.86 ± 10.07                     | 0.16      |
| Gender                            | M = 5, F = 2                       | M = 6, F = 2                          | M = 5, F = 2                      |           |
| Immunocompromised/Immunocompetent | 4/3                                | 3/5                                    | 2/5                               |           |
| APACHE-II score                   | 19.14 ± 7.4                        | 19.75 ± 4.7                           |                                   | 0.85      |
| ARDS Day of BALF collection       | 2.0 ± 1.15                         | 3.25 ± 2.19                           | 18.6 ± 13.3                       | <0.001    |
| PF Ratio on day of bronchoscopy   | 143.7 ± 34.1                       | 150 ± 71.1                            | 161.5 ± 83.7                      | 0.137     |
| BALF WBC count (cells/µl)         | 496 ± 342.6                        | 364.4 ± 408.7                         | 451.1 ± 471.5                     | 0.75      |
| BALF Neutrophils (%)              | 56.0 ± 33.3                        | 49.0 ± 38.1                           | 40.6 ± 38.5                       | 0.9327    |

*One-way analysis of variance (ANOVA) with Tukey post-test.

Statistically significant difference between late-phase survivors and early-phase survivors (p < 0.05) and between late-phase survivors and early-phase non-survivors (p < 0.05), but no difference between early-phase survivors and early-phase non-survivors.

PF ratio: PaO2 to FiO2 ratio.
doi:10.1371/journal.pone.0109713.t001

### Table 2. Pulmonary history and clinical risk factors for ARDS in the study subjects.

| Past Pulmonary History | Early-phase ARDS survivors (n = 7) | Early-phase ARDS Non-survivors (n = 8) | Late phase ARDS survivors (n = 7) |
|------------------------|------------------------------------|----------------------------------------|-----------------------------------|
| None                   | 3                                  | 6                                      | 1                                 |
| VTE                    | 1                                  | 0                                      | 0                                 |
| Smoker (prior or current) | 1                                | 0                                      | 3                                 |
| Lung infection         | 2                                  | 0                                      | 0                                 |
| COPD                   | 0                                  | 0                                      | 1                                 |
| NSCLC                  | 0                                  | 2                                      | 1                                 |
| Prior ARDS             | 0                                  | 0                                      | 1                                 |

Risk factor for ARDS

| Risk factor for ARDS | Early-phase ARDS survivors (n = 7) | Early-phase ARDS Non-survivors (n = 8) | Late phase ARDS survivors (n = 7) |
|----------------------|------------------------------------|----------------------------------------|-----------------------------------|
| Disseminated candidiasis | 1                                  | 0                                      | 0                                 |
| Sepsis               | 4                                  | 2                                      | 0                                 |
| Pneumonia, not specified | 0                                | 1                                      | 2                                 |
| Pneumonia, gram negative | 0                                | 1                                      | 2                                 |
| Pneumonia, gram positive | 0                                | 2                                      | 0                                 |
| Pneumonia, fungal     | 0                                  | 1                                      | 0                                 |
| Pneumonia, viral      | 0                                  | 0                                      | 1                                 |
| Pneumonia, aspiration | 2                                  | 0                                      | 3                                 |
| Pancreatitis          | 0                                  | 1                                      | 0                                 |
| Unknown               | 0                                  | 0                                      | 1                                 |

doi:10.1371/journal.pone.0109713.t002
In the functional annotation-clustering tool, an enrichment score of 1.3 that corresponds to a non-log scale p-value of 0.05 was used as the cutoff for significance. Functional Annotation Clustering tool was used to group related biological processes. Annotation clusters with an enrichment score according to common biological function. DAVID generates an enrichment score for a group of genes indicating annotation term member associations in a given experiment. An enrichment score of 1.3 is equivalent to a non-log scale p-value of 0.05.

**Individual Protein Quantification**

Levels for selected proteins were measured by ELISA with commercially available kits (BlueGene Life Science Advance (MUC5AC), R and D Systems, (MMP9 and SP-D), APC Biomaterials LLC (club cell secretory protein), Abcam (Kininogen, Antithrombin III, Ceruplasmin, Plasminogen, Prothrombin), MyBioSource Inc (decay-accelerating factor, thoredoxin), AssyPro (Factor 12), Cloud-Clone Corp (Moesin), CusaBio (CD9), MBL International (S100A9) and CusaBio (Ezirin).

**Results**

**Characteristics of study participants**

We analyzed BALF samples from 22 unique ARDS patients (Table 1 and Table 2): 7 in the early-phase survivor group (mean ARDS day of sample collection = 2.0 ± 1.15 days), 8 in the early phase non-survivor group (mean ARDS day of sample collection = 3.25 ± 2.19 days), and 7 in the late-phase survivor group (mean ARDS day of sample collection = 18.6 ± 13.3 days). Although the mean age of patients in the early-phase non-survivor group was higher than in the other two groups, this difference was not statistically significant (ANOVA p-value = 0.16). The three groups did not differ in the severity of gas exchange on the day of the bronchoscopy, APACHE-II score, BALF leukocyte count, or BALF neutrophil count. The average time from onset of ARDS to death in the early phase non-survivor group was 19.9 ± 14.5 days.

**Proteins identified by peptide spectral matching and database searching**

The ProteinPilot PSPEP FDR Summary reported 20,601 spectra matched to 10,355 distinct peptides at ≤ 1% global FDR for a total of 792 inferred proteins (Table S1, Protein Pilot PSPEP summary and protein identified at 1% FDR tab). High abundance proteins or their fragments (Table S1, High abundance/contaminants tab) that were incompletely removed by the depletion column were removed manually from the protein list. Suspected contaminants or misidentified proteins such as trypsin, bovine albumin, and the reverse matches that occurred from use of the target decoy strategy for peptide identification were also manually removed. After exclusion of these proteins, the number of inferred proteins was 724 (Table S1, BALF proteome tab). These 724 proteins were used as the background for GO enrichment analysis (i.e. the “universe of identified BALF proteome”). Of these 724 proteins, quantitative spectral data were available on 499 to allow determination of the bias corrected relative abundance in the two comparison groups for this study (Table S1, BALF with quantitation tab). All but three proteins had at least two peptides used for identification. Bias factors for the two comparison groups were 2.8 for the early phase non-survivors to survivors and 0.64 for early phase survivor to late phase survivor group. Bias factors were used for normalization of the protein quantification within ProteinPilot.

**Proteins differentiating early-phase survivors and early-phase non-survivors**

Controlling for an FDR of ≤ 5%, we identified 161 proteins that were differentially expressed in the BALF of early-phase survivors compared with early-phase non-survivors (Table S2, proteins with q-values ≤ 5%). Eighty-six of these proteins were more abundant in non-survivors (Table S2, high in non-survivors tab) and 75 were more abundant in survivors (Table S2, high in survivors tab). Gene ontology enrichment analysis demonstrated significant differences in the biological processes represented by these differentially expressed proteins (Figure 1). The differentially expressed proteins represented six ontologies in survivors (Table 3): three involved in coagulation (fibrinolysis and coagulation and wound healing), two representing cellular ion homeostasis, and one involved in immune activation. In contrast, differentially expressed proteins mapped to three ontologies in non-survivors (Table 4, Table S2, GO non-survivors tab). Non-survivors showed disruption of bioenergetics with evidence of carbohydrate catabolism and cellular damage as evidenced by disorganization of actin filament based processes. In addition, there was evidence of collagen biosynthesis in non-survivors early in ARDS.

**Changes in the proteome among late-phase survivors**

We identified 172 proteins (FDR at ≤ 5%) that demonstrated differential expression between early-phase and late-phase survi-
### Table 3. Early-phase ARDS Survivor Ontology Groups and Associated Proteins.

| GO Biological Process                     | Official Gene Symbol | Protein Name                              | Fold change* |
|------------------------------------------|----------------------|-------------------------------------------|--------------|
| Positive Regulation of blood coagulation  | AHSG                 | Alpha-2-HS-glycoprotein                   | 0.21         |
|                                          | APOH                 | Apolipoprotein H                          | 0.21         |
|                                          | HRG                  | Histidine-rich glycoprotein               | 0.34         |
|                                          | PLG                  | Plasminogen                               | 0.35         |
|                                          | F12                  | Coagulation factor XII                    | 0.36         |
|                                          | F2                   | Coagulation factor II                     | 0.57         |
|                                          | SERPINF2             | Serpin peptidase inhibitor, member 2      | 0.38         |
| Negative regulation of blood coagulation | AHSG                 | Alpha-2-HS-glycoprotein                   | 0.21         |
|                                          | APOH                 | Apolipoprotein H                          | 0.21         |
|                                          | KNG1                 | Kininogen 1                               | 0.24         |
|                                          | PLG                  | Plasminogen                               | 0.35         |
|                                          | F12                  | Coagulation factor XII                    | 0.36         |
|                                          | APOE                 | Apolipoprotein E                          | 0.44         |
|                                          | ANXA5                | Annexin A5                                | 0.45         |
|                                          | F2                   | Coagulation factor II                     | 0.57         |
|                                          | ANXA2                | Annexin A2                                | 0.81         |
| Regulation of body fluid levels          | SERPINC1             | Antithrombin III                          | 0.16         |
|                                          | APOH                 | Apolipoprotein H                          | 0.21         |
|                                          | KNG1                 | Kininogen 1                               | 0.24         |
|                                          | PLG                  | Plasminogen                               | 0.35         |
|                                          | F12                  | Coagulation factor XII                    | 0.36         |
|                                          | ANXA5                | Annexin A5                                | 0.45         |
|                                          | F2                   | Coagulation factor II                     | 0.57         |
|                                          | ANXA2                | Annexin A2                                | 0.81         |
| Cellular cation homeostasis              | KNG1                 | Kininogen 1                               | 0.24         |
|                                          | HPX                  | Hemopexin                                 | 0.30         |
|                                          | SFTPD                | Surfactant protein D                      | 0.38         |
|                                          | APOE                 | Apolipoprotein E                          | 0.44         |
|                                          | F2                   | Coagulation factor II                     | 0.57         |
|                                          | FTL                  | Ferritin, light polypeptide               | 0.62         |
|                                          | FTH1                 | Ferritin, heavy polypeptide 1             | 0.62         |
|                                          | S5                   | Decay accelerating factor                 | 0.78         |
|                                          | CP                   | Ceruloplasmin                             | 0.84         |
| Iron ion homeostasis                     | HPX                  | Hemopexin                                 | 0.30         |
|                                          | FTH1                 | Ferritin, heavy polypeptide 1             | 0.62         |
|                                          | FTL                  | Ferritin, light polypeptide               | 0.62         |
|                                          | CP                   | Ceruloplasmin                             | 0.84         |
| Positive regulation of immune response   | C4BPA                | Complement component 4 binding protein, alpha | 0.09 |
|                                          | PLG                  | Plasminogen                               | 0.35         |
|                                          | F12                  | Coagulation factor XII                    | 0.36         |
|                                          | CFH                  | Complement factor H-related 2             | 0.45         |
|                                          | C1RL                 | Complement component 1r                   | 0.56         |
|                                          | F2                   | Coagulation factor II                     | 0.57         |
|                                          | CLU                  | Histone cluster 1,                        | 0.65         |
|                                          | C5                   | Complement component 5                    | 0.66         |
|                                          | KRT1                 | Keratin 1                                 | 0.67         |
vors of ARDS (Table S3, FDR q-values tab). Of these 172 proteins, 91 were more abundant in early-phase ARDS survivors (Table S3, high in early phase tab) and 81 were more abundant in late-phase ARDS survivors (Table S3, high in late phase tab). Gene ontology enrichment analysis employing the functional annotation-clustering tool in DAVID identified three ontology annotations that were over represented in early-phase survivors: lymphocyte and leukocyte immune response, cellular cation homeostasis, and iron ion homeostasis (Table S3, GO early phase tab). In contrast, proteins that were more abundant in late-phase survivors represented two clusters of ontologies involved in lung repair: cell migration and actin cytoskeleton organization (Figure 2 and Table S2, GO late phase tab).

Changes in key proteins concentrations in individual samples

As we used pooled samples for our proteomic studies, we measured protein concentration from individual BALF samples by ELISA. Similar to the MS data, the level of club cell secretory protein was significantly higher in early phase non-survivors when compared to early phase survivors (2458±1409 vs. 922±534 ng/mL, p-value = 0.048, figure 3a). Moesin (1.02±0.52 vs. 2.63±1.76 ng/ml, p-value 0.055, Figure 3b) and MMP 9 (93.51±133.1 vs. 10±11.87 ng/mL, p-value = 0.19, figure 3c) demonstrated a non-significant increase in early phase non-survivors compared to survivors. Although MUC5A was higher in survivors, it did not reach statistical significance (10.74±4.16 vs. 4.499±3.48, p-value = 0.29 whereas SP-D was not different.

To develop a panel of candidate proteins that could discriminate early phase survivors from non-survivors, we measured BALF levels of several key proteins that were higher in survivors

Table 3. Cont.

| GO Biological Process | Official Gene Symbol | Protein Name                  | Fold change* |
|-----------------------|----------------------|-------------------------------|--------------|
| CD55                  | Decay accelerating factor | 0.78                         |              |
| C8A                   | Complement component 8, alpha | 0.79                      |              |
| C6                    | Complement component 6 | 0.80                         |              |
| APOH                  | Apolipoprotein H      | 0.21                         |              |

*Fold change is relative to survivors, therefore a fold change <1 represents proteins more abundant in survivors.
doi:10.1371/journal.pone.0109713.t003

Table 4. Early-phase ARDS Non-Survivor Ontology Groups and Associated Proteins.

| GO Biological Process                | Official Gene Symbol | Protein Name                  | Fold change  |
|--------------------------------------|----------------------|-------------------------------|--------------|
| Actin filament-based process          | TMSB4X               | Thymosin-like 2               | 2.65         |
|                                      | EZR                  | Ezrin                         | 2.15         |
|                                      | PFN1                 | Profilin 1                    | 1.93         |
|                                      | VASP                 | Vasodilator-stimulated phosphoprotein | 1.81     |
|                                      | CAP1                 | Adenylate cyclase-associated protein 1 | 1.58         |
|                                      | ARHGIDB              | Rho GDP dissociation inhibitor (GDI) beta | 1.52     |
|                                      | S100A9               | S100 calcium binding protein A9 | 1.51         |
|                                      | FLNA                 | Filamin A, alpha              | 1.31         |
|                                      | MYH9                 | Non-muscle myosin, heavy chain 9 | 1.27         |
|                                      | STMN1                | Stathmin 1                    | 1.20         |
| Glycolysis                           | GAPDH,6              | Glyceraldehyde-3-phosphate dehydrogenase-like 6 | 2.01     |
|                                      | TXN                  | Thioredoxin                   | 1.82         |
|                                      | PGK1                 | Phosphoglycerate kinase 1      | 1.73         |
|                                      | TPII                 | Triosephosphate isomerase 1    | 1.63         |
|                                      | GPI                  | Glucose phosphate isomerase    | 1.63         |
|                                      | ENO1                 | Enolase 1, (alpha)             | 1.51         |
|                                      | PGAM1                | Phosphoglycerate mutase 1      | 1.42         |
| Collagen metabolic process           | COL5A1               | Type V collagen, alpha 1       | 2.33         |
|                                      | MUC5AC               | Mucin 5AC                     | 2.04         |
|                                      | COL3A1               | Type III collagen alpha 1      | 1.99         |
|                                      | MMP9                 | Matrix metalloproteinidase 9  | 1.84         |
|                                      | COL1A1               | Type I collagen, alpha 1       | 1.75         |

doi:10.1371/journal.pone.0109713.t004
The BALF protein expression profile for patients early in ARDS was different comparing survivors to non-survivors. Patients who died had evidence of aberrant lung repair early on in the disease process, as evidenced by approximately a two-fold differential expression of type I, III and V collagen, a signature of activated fibroblasts, and newly synthesized collagen deposition. This is in line with previous reports that higher levels of collagen I and III in ARDS [41] reflect matrix remodeling locally in the lung. Increased levels of BALF type III procollagen also correlated with fatal outcomes in ARDS [42]. In contrast, survivors early in the disease course demonstrated a more coordinated response that includes coagulation as the focal point, including plasminogen-mediated fibrinolysis. The balance of activation of coagulation and fibrinolysis is an important determination of the extent of fibrin deposition. In previous studies, tissue factor mediated procoagulant [43], protein C mediated anti-coagulant [44], and plasminogen mediated fibrinolysis pathways appeared to be important in ARDS [45]. Up-regulation of plasminogen activator inhibitor in BALF suggests a shift from a pro-fibrinolytic to an anti-fibrinolytic phenotype being associated with poorer outcomes [46]. In our study, a similar pattern of active collagen deposition suggesting an anti-fibrinolytic milieu even in the exudative phase in ARDS non-survivors is seen, while ARDS survivors have a more prominent fibrinolytic milieu. This indicates a profound difference in response to alveolar injury in survivors compared to non-survivors.

In addition to abnormal repair, non-survivors also have evidence of increased catabolism and cellular disruptions. In contrast, survivors demonstrate a coordinated activation of cation and iron homeostasis. Prior studies have shown the importance of iron in the development of ARDS [47,48]. Cell and tissue damage resulting from inflammatory/oxidative stress can ultimately be a consequence of disruption of normal iron metabolism. Patients with ARDS have increased concentrations of heme and non-heme iron that could lead to generation of oxidative stress and resultant lung damage [49]. Polymorphisms in ferritin light chain and heme-oxygenase have also been associated with increased susceptibility to ARDS [50]. In survivors, higher levels of several proteins involved in iron regulation such as ferritin heavy and light chain, hemopexin, and cerruloplasmin indicate better capacity to counteract the redox stress mediated by iron or other reactive oxygen species in the lungs.

In addition to giving insight into mechanisms of disease, differentially expressed proteins in the early phase of ARDS can be used to discern non-survivors from survivors for prognostication. The ideal biomarker would have biological significance related to lung injury and repair. Alternatively, a panel of proteins that represent the divergent biological processes in the two groups

Figure 3. Protein levels of selected candidates. ELISA was performed to quantify CCSP, Moesin and MMP9. Levels of these proteins were higher in early phase non-survivors in comparison to survivors (p-value <0.05 t-test) for CCSP and <0.1 for Moesin. doi:10.1371/journal.pone.0109713.g003
could be selected for testing in a separate cohort of well phenotyped patients. As the proteomic platform that we used only provides relative quantitation, complementary studies using multiplex ELISA or multiple reaction monitoring will be needed to measure absolute levels to select a limited number of proteins that could be further investigated. We used ELISA for measurement of protein levels for two main reasons. First, this provided validation that mass spectrometric measures of the protein amounts were

Figure 4. Protein levels of selected proteins that represent biological processes that are activated in early phase survivors (p-value plasminogen = 0.06, antithrombin III = 0.054, factor 12 = 0.2 and ceruloplasmin = 0.9).

Figure 5. Protein levels of selected proteins that represented biological processes that are activated in early phase non-survivors. Thioredoxin was identified in only 3 survivors. (p-value <0.05 thioredoxin and <0.1 for S-100).

DOI:10.1371/journal.pone.0109713.g004

DOI:10.1371/journal.pone.0109713.g005
accurate. The fold change for CCSP (spot P11684 | UTER_HUMAN) in Table S2, high in non-survivor tab, row 25) was 6.2 fold in the mass spectrometric studies. In line with these findings, the mean levels measured with ELISA demonstrated a >4.5 fold higher abundance in the protein level. Similarly, other proteins produced in the lung, Moesin, MMP9 and MUC5A, also demonstrated a trend toward higher levels in non-survivors by ELISA and mass spectrometry studies, whereas surfactant D did not demonstrate a significant change when measured in individual BALF samples. These proteins could represent epithelial damage and be candidate proteins to test in a larger cohort of well phenotyped subjects with ARDS.

CCSP is produced by small airway cells and has been implicated in regulating inflammatory responses in the lung. In patients with ventilator associated pneumonia, serum CCSP levels increased 2 days before the diagnosis of ARDS/ALI [51]. However, data regarding the utility of plasma CCSP levels is conflicting in small studies with one study demonstrating evidence in CCSP predicting mortality [52], while another study did not find any association of serum CCSP levels with mortality [53]. Our study suggests BALF CCSP levels alone or conjunction with other proteins could be marker of epithelial damage and could predict mortality in ARDS.

ERM (ezrin-radixin-moesin) proteins co-localize in cell matrix adhesion sites, filopodia, and membrane protrusions [54]. ERMs function by binding to and organizing the actin cytoskeleton [55] and in turn, stabilizing adherens junctions [56] and influencing cell migration [57,58]. In adult wild-type mice, moesin expression is limited to the alveolar epithelium of the distal lung. Moesin-deficient mice develop normally [59] demonstrate decreased moesin in the distal alveolar wall and have airspace enlargement. In response to bleomycin, moesin-deficient mice had lower survival [60], more inflammation, extensive alveolar destruction, hemorrhage and pulmonary edema, increased lung permeability, and a higher total BALF cell count. In moesin-deficient mice, fibrotic response to bleomycin was both earlier and more severe. This supports involvement of moesin in injury-repair response in the lung.

Matrix metalloproteinase (MMP) are proteases that are involved degradation of extracellular matrix. Type IV collagen is specific to the basement membrane and MMP-9 is a type IV collagenase. In ARDS, BALF MMP-9 levels were high compared to controls and correlated with degree of collagen breakdown as determined by measuring collagen breakdown products (7S collagen) [61]. Early elevations of MMP-9 levels have also been found to be associated with prolonged duration of mechanical ventilation in pediatric ARDS patients [62]. In our study, although we did not compare the BALF MMP-9 level in ARDS with controls, higher BALF MMP-9 were seen in patients who died. Though speculative, this could be a marker of worse epithelial damage in non-survivors. In addition we also measured MUC5A levels in the BALF by ELISA. MUC5A is a member of the mucins, large glycoproteins that form a protective biofilm covering the respiratory epithelial lining. MUC5A is secreted mostly by the surface epithelial goblet cells [63]. MUC5AC transcripts levels increase in airway epithelial cells upon cyclic stretch, in mice with ventilator induced lung injury and in humans with ARDS [63]. Though the proteins levels of MUC5AC in our studies did not differentiate survivors and non-survivors, this may have resulted from our relatively small sample.

In this study we also compared the BALF protein expression profiles of early- and late- phase survivors. This comparison highlights the dynamic changes in the airspace milieu during repair. Chang and colleagues [36] characterized BALF in ARDS patients on day 1, 3, and 7; their results demonstrated striking differences between normal controls and ARDS patients on day 1, but less dramatic changes between days 1, 3 and 7. The changes seen in their studies reflected alteration in the innate immune and oxidant pathways at day 3 and possibly lung regeneration at day 7. Similar to that study, we found that activation of the innate immune system and cation homeostasis were over-represented by proteins in early-phase survivors compared to late-phase survivors. However, in our late-phase survivors – whose samples were obtained 18 days after the onset of ARDS, much later than in previous studies – the ontologies were drastically different and included cell migration and actin cytoskeleton organization. Since all of these patients survived, these findings suggest a critical role of these processes during lung repair. The proteins that are represented in these ontologies could be potential targets to stimulate repair mechanisms as potential molecular targets for therapy in ARDS.

We acknowledge the limitations of our study. We were limited by the amount of available BALF therefore are the protein characterization was performed on pooled BALF samples. Pooled samples are subject to influence by a minority of outliers within the pool. We were limited to a single run for the mass-spectrometry, whereas surfactant D did not demonstrate a significant change when measured in individual BALF samples. These proteins could represent epithelial damage and be candidate proteins to test in a larger cohort of well phenotyped subjects with ARDS.

ERM (ezrin-radixin-moesin) proteins co-localize in cell matrix adhesion sites, filopodia, and membrane protrusions [54]. ERMs function by binding to and organizing the actin cytoskeleton [55] and in turn, stabilizing adherens junctions [56] and influencing cell migration [57,58]. In adult wild-type mice, moesin expression is limited to the alveolar epithelium of the distal lung. Moesin-deficient mice develop normally [59] demonstrate decreased moesin in the distal alveolar wall and have airspace enlargement. In response to bleomycin, moesin-deficient mice had lower survival [60], more inflammation, extensive alveolar destruction, hemorrhage and pulmonary edema, increased lung permeability, and a higher total BALF cell count. In moesin-deficient mice, fibrotic response to bleomycin was both earlier and more severe. This supports involvement of moesin in injury-repair response in the lung.

Matrix metalloproteinase (MMP) are proteases that are involved degradation of extracellular matrix. Type IV collagen is specific to the basement membrane and MMP-9 is a type IV collagenase. In ARDS, BALF MMP-9 levels were high compared to controls and correlated with degree of collagen breakdown as determined by measuring collagen breakdown products (7S collagen) [61]. Early elevations of MMP-9 levels have also been found to be associated with prolonged duration of mechanical ventilation in pediatric ARDS patients [62]. In our study, although we did not compare the BALF MMP-9 level in ARDS with controls, higher BALF MMP-9 were seen in patients who died. Though speculative, this could be a marker of worse epithelial damage in non-survivors. In addition we also measured MUC5A levels in the BALF by ELISA. MUC5A is a member of the mucins, large glycoproteins that form a protective biofilm covering the respiratory epithelial lining. MUC5A is secreted mostly by the surface epithelial goblet cells [63]. MUC5AC transcripts levels increase in airway epithelial cells upon cyclic stretch, in mice with ventilator induced lung injury and in humans with ARDS [63]. Though the proteins levels of MUC5AC in our studies did not differentiate survivors and non-survivors, this may have resulted from our relatively small sample.

In this study we also compared the BALF protein expression profiles of early- and late- phase survivors. This comparison highlights the dynamic changes in the airspace milieu during repair. Chang and colleagues [36] characterized BALF in ARDS patients on day 1, 3, and 7; their results demonstrated striking differences between normal controls and ARDS patients on day 1, but less dramatic changes between days 1, 3 and 7. The changes seen in their studies reflected alteration in the innate immune and oxidant pathways at day 3 and possibly lung regeneration at day 7. Similar to that study, we found that activation of the innate immune system and cation homeostasis were over-represented by proteins in early-phase survivors compared to late-phase survivors. However, in our late-phase survivors – whose samples were obtained 18 days after the onset of ARDS, much later than in previous studies – the ontologies were drastically different and included cell migration and actin cytoskeleton organization. Since all of these patients survived, these findings suggest a critical role of these processes during lung repair. The proteins that are represented in these ontologies could be potential targets to stimulate repair mechanisms as potential molecular targets for therapy in ARDS.

Conclusion

This study illustrates a framework whereby protein profiling can be used to identify panels of proteins that parallel the pathophysiological changes occurring in ARDS. We demonstrate dynamic changes in BALF protein expression during the course of ARDS and also early divergence in the protein expression profile in ARDS. Differences in absolute levels of the proteins that represent divergent biological processes in survivors and non-survivors will facilitate identification of prognostic biomarkers in ARDS.

Supporting Information

Table S1 BALF proteins identified using iTRAQ MS/MS.
(XLSX)

Table S2 Differentially expressed proteins between early phase survivors and non survivors.
(XLSX)

Table S3 Differentially expressed proteins between early and late phase survivors.
(XLSX)
Acknowledgments

The authors thank Dr. LeeAnn Higgins for acquisition of mass spectrometry data and Dr. Anne Marie Weber-Main for her critical review and editing of manuscript drafts. The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium [32] via the PRIDE partner repository with the dataset identifier PXD001095.

Author Contributions

Conceived and designed the experiments: MB DHH VK CHW PDJ. Performed the experiments: MB TLB KJV. Analyzed the data: MB BW SD MSS PDJ CHW. Contributed reagents/materials/analysis tools: MB DHI CHW. Wrote the paper: PDJ MSS PBB CHW.

References

1. Ashbaugh DG, Bigelow DB, Petty TL, Levine BE (1967) Acute respiratory distress in adults. Lancet 2: 319–323.
2. Surat BT, Parsons PE (2006) Mechanisms of acute lung injury/acute respiratory distress syndrome. Clinics in chest medicine 27: 579–589; abstract viii.
3. Rubenfeld GD, Caldwell E, Peabody E, Weaver J, Martin DP, et al. (2005) Incidence and outcomes of acute lung injury. The New England journal of medicine 353: 1685–1693.
4. Rubenfeld GD, Herridge MS (2007) Epidemiology and outcomes of acute lung injury. Chest 131: 534–562.
5. Wiedemann HP, Wheeler AP, Bernard GR, Thompson BT, Hayden D, et al. (2006) Comparison of two fluid-management strategies in acute lung injury. The patients with acute lung injury. American journal of respiratory and critical care medicine 174: 2533–2556.
6. Gürün C, Reigner J, Richard JC, Bequet P, Gacquin A, et al. (2013) Prone Positioning in Severe Acute Respiratory Distress Syndrome. The New England journal of medicine.
7. (2000) Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury/adult respiratory distress syndrome. The American journal of physiology Lung cellular and molecular physiology 285: L514–521.
8. Levy RM, Dellinger RP, Townsend SR, Linde-Zwirble WT, Carlet J, et al. (2003) Antibiotics for the treatment of acute lung injury. The New England journal of medicine 348: 1763–1777.
9. Cohen MJ, Brohi K, Calfee CS, Rahn P, Chesebro BB, et al. (2009) Early release of high-sensitivity troponin I after severe trauma in humans: role of injury severity and tissue hypoperfusion. Critical care medicine 37: 1319–1326.
10. Calfee CS, Ware LB, Greene KE, Nuckton TJ, Eisner MD, et al. (2003) Acute lung injury–new therapeutic targets? The Keio journal of medicine 54: 142–149.
11. Prabhakaran P, Ware LB, White KE, Cross MT, Matthay MA, et al. (2003) Determining the aetiology of pulmonary oedema by the oedema fluid-to-plasma soluble TNF receptors are associated with morbidity and mortality in patients with acute lung injury. American journal of physiology Lung and molecular physiology 288: L246–319.
12. Wirz B, Eisner MD, Thompson BT, Parsons PE, Matthay MA (2004) Significance of von Willebrand factor in septic and nonseptic patients with acute lung injury. American journal of respiratory and critical care medicine 170: 766–772.
13. Ware LB, Matthay MA, Parsons PE, Thompson BT, Januzi JL, et al. (2007) Pathogenetic and prognostic significance of altered coagulation and fibrinolysis in acute lung injury/acute respiratory distress syndrome. Critical care medicine 35: 1821–1829.
14. Ware LB, Koyama T, Bilheimer DD, Wu W, Bernard GR, et al. (2010) Prognostic and pathogenetic value of combining clinical and biochemical indices in patients with acute lung injury. Chest 137: 280–296.
15. Cribbs SK, Martin GS (2008) Biomarkers in acute lung injury: are we making progress? Critical care medicine 36: 2457–2459.
16. Knaus WA, Draper EA, Wagner DP, Zimmerman JE (1985) APACHE II: a severity of disease classification system. Crit Care Med 13: 818–829.
17. Zhang Y, Worblewski M, Hertz MI, Wendt CH, Corverna TM, et al. (2006) Analysis of chronic lung transplant rejection by MALDI-TOF profiles of bronchoalveolar lavage fluid. Proteomics 6: 1001–1010.
18. Griffin T, Chilton J, Johnson J, de Jong E, Onsongo G, et al. (2013) Galaxy-P: Transforming MS-based proteomic informatics via innovative workflow development, dissemination, standardization and transparency. American Society of Mass Spectrometry and Allied Topics. Minneapolis, USA.
19. Viarcaio JA, Deutsch EW, Wang R, Csordas A, Reisinger F, et al. (2014) ProteomeXchange provides globally coordinated proteomics data submission and dissemination. Nat Biotechnol 32: 223–226.
20. Storey JD (2002) A direct approach to false discovery rates. J R Statist Soc 64: 470–498.
21. Huang da W, Sherman BT, Lempicki RA (2009) Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nature protocols 4: 44–57.
22. Gharib SA, Nguyen E, Altermeyer WA, Shaffer SA, Donecau CE, et al. (2010) Of mice and men: comparative proteomics of bronchoalveolar fluid. The European respiratory journal 35: 1380–1390.
23. Chuang DW, Hayashi S, Gharib SA, Vaisar T, King NT, et al. (2008) Proteomic and computational analysis of bronchoalveolar lavage proteins during the course of the acute respiratory distress syndrome. American journal of respiratory and critical care medicine 178: 701–707.
24. Kosanam H, Sato M, Bartruch I, Smith C, Keshavjee S, et al. (2012) Differential proteomic analysis of bronchoalveolar lavage fluid from lung transplant patients with and without chronic graft dysfunction. Clinical biochemistry 45: 225–230.
25. Mao A, Bini L, Perazi MG, Thakur A, Sanchez JC, et al. (2002) Bronchoalveolar lavage fluid protein composition in patients with sarcoidosis and idiopathic pulmonary fibrosis: a two-dimensional electrophoretic study. Electrophoresis 23: 3439–3447.
26. Meckel D, Rist W, Seifert P, Weith A, Lenter MC (2005) Proteomic study of human bronchoalveolar lavage fluids from smokers with chronic obstructive pulmonary disease by combining surface-enhanced laser desorption/ionization-mass spectrometry profiling with mass spectrometric protein identification. Proteomics 5: 2972–2980.
27. Wu J, Kobayashi M, Sousa EA, Liu W, Cai J, et al. (2005) Differential proteomic analysis of bronchoalveolar lavage fluid in asthmatics following segmental antigen challenge. Molecular & cellular proteomics: MCP 4: 1251–1264.
28. Fajrjeil J, Hartmann DJ, Guidet B, Loup C, Offenstein G (1993) Four markers of collagen metabolism as possible indicators of disease in the adult respiratory distress syndrome. The American review of respiratory disease 147: 1081–1099.
29. Clark JG, Millberg JA, Steinberg KP, Hudson LD (1995) Type III procollagen peptide in the adult respiratory distress syndrome. Association of increased peptide levels in bronchoalveolar lavage fluid with increased risk for death. Annals of internal medicine 122: 17–23.
30. Idel S, Koenig KB, Fair DS, Martin TR, McLaroy J, et al. (1991) Serial abnormalities of fibrin turnover in evolving adult respiratory distress syndrome. The American journal of physiology 261: L240–248.
31. Ware LB, Fang X, Matthay MA (2003) Protein C and thrombomodulin in human acute lung injury. American journal of physiology Lung and molecular physiology 288: L246–319.
32. Vizcaino JA, Deutsch EW, Wang R, Csordas A, Reisinger F, et al. (2014) ProteomeXchange provides globally coordinated proteomics data submission and dissemination. Nat Biotechnol 32: 223–226.
are associated with mortality in acute lung injury. American journal of physiology Lung cellular and molecular physiology 285: L20–28.

47. Quinlan GJ, Chen Y, Evans TW, Gutteridge JM (2001) Iron signalling regulated directly and through oxygen: implications for sepsis and the acute respiratory distress syndrome. Clinical science 100: 169–182.

48. Connelly KG, Moss M, Parsons PE, Moore EE, Moore FA, et al. (1997) Serum ferritin as a predictor of the acute respiratory distress syndrome. American journal of respiratory and critical care medicine 155: 21–25.

49. Glio AJ, Carter JD, Richards JH, Kircher LD, Grissom CK, et al. (2003) Iron and iron-related proteins in the lower respiratory tract of patients with acute respiratory distress syndrome. Critical care medicine 31: 395–400.

50. Lagan AL, Quinlan GJ, Mumby S, Melley DP, Goldstraw P, et al. (2008) Variation in iron homeostasis genes between patients with ARDS and healthy control subjects. Chest 133: 1302–1311.

51. Determann RM, Millo JL, Waddy S, Lutter R, Garrard CS, et al. (2009) Plasma CC16 levels are associated with development of ALI/ARDS in patients with ventilator-associated pneumonia: a retrospective observational study. BMC Pulm Med 9: 49.

52. Lesur O, Langesen S, Berthiaume Y, Legare M, Skrobak Y, et al. (2006) Outcome value of Clara cell protein in serum of patients with acute respiratory distress syndrome. Intensive Care Med 32: 1167–1174.

53. Kropski JA, Fremont RD, Calfee CS, Ware LB (2009) Clara cell protein (CC16), a marker of lung epithelial injury, is decreased in plasma and pulmonary edema fluid from patients with acute lung injury. Chest 135: 1440–1447.

54. Berryman M, Franck Z, Brencher A (1993) Ezrin is concentrated in the apical microvilli of a wide variety of epithelial cells whereas moesin is found primarily in endothelial cells. J Cell Sci 105 (Pt 4): 1025–1043.

55. Niggli V, Rossy J (2008) Ezrin/radixin/moesin: versatile controllers of signaling molecules and of the cortical cytoskeleton. Int J Biochem Cell Biol 40: 344–349.

56. Mangeat P, Roy C, Martin M (1999) ERM proteins in cell adhesion and membrane dynamics. Trends Cell Biol 9: 187–192.

57. Arpin M, Chavvin D, Naba A, Zwaanepoel I (2011) Emerging role for ERM proteins in cell adhesion and migration. Cell Adh Migr 5: 199–206.

58. Okayama T, Kikuchi S, Ochiai T, Iwama H, Kubota T, et al. (2008) Attenuated response to liver injury in moesin-deficient mice: impaired stellate cell migration and decreased fibrosis. Biochem Biophys Acta 1782: 542–548.

59. Doi Y, Itoh M, Yonemura S, Ishihara S, Takano H, et al. (1999) Normal development of mice and unimpaired cell adhesion/cell mobility/actin-based cytoskeleton without compensatory up-regulation of ezrin or radixin in moesin gene knockout. J Biol Chem 274: 2315–2321.

60. Hashimoto S, Amaya F, Matsuyama H, Urno H, Kikuchi S, et al. (2008) Dysregulation of lung injury and repair in moesin-deficient mice treated with intratracheal bleomycin. Am J Physiol Lung Cell Mol Physiol 295: L566–574.

61. Torii K, Iida K, Miyazaki Y, Saga S, Konoh Y, et al. (1997) Higher concentrations of matrix metalloproteinases in bronchoalveolar lavage fluid of patients with adult respiratory distress syndrome. Am J Respir Crit Care Med 155: 43–46.

62. Kong MY, Li Y, Oster R, Gaggar A, Clancy JP (2011) Early elevation of matrix metalloproteinase-9 in pediatric ARDS is associated with an increased risk of prolonged mechanical ventilation. PLoS One 6: e22596.

63. Kroppen M, McNamee EN, Beodsky KS, Ahern CM, Faige M, et al. (2013) Detrimental role of the airway mucin Mac3ac during ventilator-induced lung injury. Mucosal Immunol 6: 762–775.